Citations

Mayo Clinic

Clear

93 citation(s) found for "O’Brien, Peter".

Primary CNS Lymphoma of T-Cell Origin: A Descriptive Analysis From the International Primary CNS Lymphoma Collaborative Group
Shenkier, Tamara , Blay, Jean‐Yves , Poortmans, Philip , Thiel, Eckhard, Jahnke, Kristoph, Abrey, Lauren E. , Neuwelt, Edward A. , Tsang, Richard , Batchelor, Tracy T. , Ferreri, Andrés J.M. , O’Brien, Peter, Rubenstein, James L. , O’Neill, Brian Patrick , Harris, Nancy L. , Ponzoni, Maurilio , Connors, Joseph M. , Blay, Jean-Yves

Journal of Clinical Oncology | March 30, 2005 | Volume: 23 | Issue: 10 | Pages: 2233-2239

10.1200/jco.2005.07.109 | PMID 15800313 Get It

Purpose To describe the demographic and tumor related characteristics and outcomes for patients with primary T-cell CNS lymphoma (TPCNSL). Patients and Methods A retrospective series of patients with TPCNSL was compiled from twelve cancer centers in seven countries. Results We identified 45 patients with a median age of 60 years (range, 3 to 84 years). Twenty (44%) had Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1. Twenty-six (58%) had involvement of a cerebral hemisphere and sixteen (36%) had lesions of deeper sites in the brain. Serum lactate dehydrogenase was elevated in 7 (32%) of 22 patients, and CSF protein was elevated in 19 of 24 patients (79%) with available data. The median disease-specific survival (DSS) was 25 months (95% CI, 11 to 38 months). The 2- and 5-year DSS were 51% (95% CI, 35% to 66%) and 17% (95% CI, 6% to 34%), respectively. Univariate and multivariate analyses were conducted for age (≤ 60 v > 60 years), PS (0 or 1 v 2, 3, or 4), involvement of deep structures of the CNS (no v yes), and methotrexate (MTX) use in the primary treatment (yes v no). Only PS and MTX use were significantly associated with better outcome with hazard ratios of 0.2 (95% CI, 0.1 to 0.4) and 0.4 (95% CI, 0.2 to 0.8), respectively. Conclusion This is the largest series ever assembled of TPCNSL. The presentation and outcome appear similar to that of B cell PCNSL. PS 0 or 1 and administration of MTX are associated with better survival.
A Rank-Sum-Type Test for Paired Data with Multiple Endpoints
Karrison, Theodore , O’Brien, Peter C.

Journal of Applied Statistics | January 8, 2004 | Volume: 31 | Issue: 2 | Pages: 229-238

10.1080/0266476032000148885 Get It

Familial Clustering of Stroke According to Proband Age at Onset of Presenting Ischemic Stroke
Atkinson, Elizabeth J. , O’Brien, Peter C. , Brott, Thomas G. , Brown, Robert D., Hardy, John , Meschia, James F. , Hardy, John

Stroke | June 24, 2003 | Volume: 34 | Issue: 7 | Pages: No page available

10.1161/01.str.0000078312.07274.a4 | PMID 12817106 Get It

Background and Purpose— The magnitude of inherited risk of stroke may lessen with age, and this would have implications for optimizing genomic approaches to identifying genetic risk factors for stroke. We investigated the relationship between age and inherited risk of stroke. Methods— Family histories of stroke were obtained in systematic interviews with 310 adult men and women with recent CT- or MR-confirmed ischemic stroke. Probability of stroke in first-degree relatives was analyzed by logistic regression, adjusting for sibship size. Results— The probability of having a sibling with stroke increased as proband age at stroke presentation increased. Per decade increase in proband age, the odds ratio was 1.65 (95% confidence interval [CI], 1.20 to 2.28; P =0.002) for a concordant sibling and 1.69 (95% CI, 1.15 to 2.49; P =0.008) for ≥2 first-degree relatives with a history of stroke. Conclusions— Clustering of stroke was not greater in families with probands manifesting symptoms of stroke in earlier than later adulthood. The relationship between proband age and positive family history of stroke does not suggest an upper age-limit cutoff for genomewide linkage studies.